SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Charles Schwab is trending as a new AI tool for tax planning from Altruist Corp. sparks concerns about industry disruption, leading to a broader sell-off across financial stocks. Community sentiment is divided, with some calling the market's reaction overdone while others are vocal about ongoing frustrations with Schwab's platform and trading restrictions.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart is navigating intense investor speculation ahead of its earnings report, fueling a stark divide between bulls anticipating a significant short squeeze driven by its AI lending model and critics lamenting consistent underperformance and management's perceived lack of communication. The broader fintech sector's volatility and concerns over consumer credit health continue to weigh heavily on community sentiment, making the stock a focal point for both potential rebound and further weakness.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X is trending as its merger target, Infleqtion, secures significant contracts in quantum space and energy technology, leading the community to view it as undervalued ahead of its imminent debut as INFQ and its strong positioning against industry peers.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Senseonics is trending following its CE Mark approval for the Eversense 365 CGM system in Europe and the launch of its first commercial integration with an automated insulin delivery (AID) system, driving community excitement about market adoption and the potential for a significant short squeeze.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is trending due to a strong Q4 earnings beat and optimistic outlook, with the community highlighting reaccelerated revenue growth and surging RPO driven by both core and AI-native customers. This robust performance is viewed as a significant positive signal for the broader software sector, suggesting a potential end to its recent slowdown.

Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.

Evommune Inc.

Evommune Inc

Evommune (EVMN) is experiencing significant market interest following positive top-line data from its Phase 2a trial for EVO301, an eczema treatment that met its primary endpoint. The announcement has sparked a heated debate among traders, with many anticipating a short squeeze while others express caution regarding its valuation.

American Superconductor Corp. engages in the provision of megawatt-scale power solutions. Its products include electric control systems, generators & drivetrains, power converters, renewable interconnectivity solutions, software, turbine designs, utility and industrial resilience and modernization solutions, and utility voltage solutions. It operates through the Grid and Wind segments. The Grid segment enables electric utilities and renewable energy project developers to connect, transmit, and distribute power with efficiency, reliability, security, and affordability. The Wind segment permits the manufacturers to field wind turbines with power output, reliability, and affordability. The company was founded by Yet Ming Chiang, David A. Rudman, John B. Vander Sande, and Gregory J. Yurek on April 9, 1987 and is headquartered in Ayer, MA.

American Superconductor Corp.

AMSC is gaining traction after reporting strong earnings and an optimistic outlook, fueling investor excitement around its potential for significant involvement in critical grid modernization and the booming AI data center infrastructure market, with community speculation about a notable connection to Microsoft Azure. Many believe the stock is currently undervalued and positioned for a breakout.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia is actively discussed following its recent earnings report, which showcased significant revenue and GMV growth, substantially reduced losses, and a reaffirmed trajectory towards profitability. While some investors are buying the dip and reinforcing their long-term conviction in Jumia as Africa's leading e-commerce player, others are reacting to short-term volatility in what some perceive as a 'sell the news' event.

Ichor Holdings Ltd. engages in designing, engineering, and manufacturing fluid delivery subsystems for semiconductor capital equipment. It offers gas and chemical delivery systems, which are key elements of the process tools used in the manufacturing of semiconductor devices. The firm also manufactures precision machined components, weldments, and proprietary products for use in fluid delivery systems for direct sales to its customers. The company was founded in 1999 and is headquartered in Fremont, CA.

Ichor Holdings Ltd

Ichor Holdings is rallying sharply following strong Q4 earnings and robust revenue growth, driven by its critical fluid delivery systems for the semiconductor industry. The community is actively discussing its potential as a major beneficiary of increasing HBM and AI demand, further fueled by speculation around favorable implications from proposed semiconductor tariffs for US-based manufacturers.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is trending after a mixed earnings report, where an EPS beat was contrasted by a revenue miss and modest guidance, fueling community debate over its perceived deep value at a low forward P/E versus ongoing concerns about its balance sheet and broader fintech sector headwinds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of +21.50% and +19.52%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Enanta Pharmaceuticals (NASDAQ:ENTA) Posts Earnings Results, Beats Estimates By $0.12 EPS

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) posted its earnings results on Monday. The biotechnology company reported ($0.42) earnings per share for the quarter, beating the consensus...

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven research firms that are covering the firm, MarketBeat...

Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections and immunological...

Agios Pharmaceuticals (AGIO) Surges 18.6%: Is This an Indication of Further Gains?

Agios Pharmaceuticals (AGIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven research firms that are presently covering the firm...

Enanta Pharmaceuticals (ENTA) Surges 5.9%: Is This an Indication of Further Gains?

Enanta Pharmaceuticals (ENTA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Enanta Pharmaceuticals (NASDAQ:ENTA) Share Price Crosses Above 200-Day Moving Average - What's Next?

Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price Passes Above 200-Day Moving Average - Should You Sell...

Insider Selling: Enanta Pharmaceuticals (NASDAQ:ENTA) Insider Sells 1,394 Shares of Stock

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) insider Brendan Luu sold 1,394 shares of the company's stock in a transaction dated Friday, December 5th. The shares were sold at an...

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

ENTA
Enanta Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ENTA News

ENTAEnanta Pharmaceuticals Inc